Clinicopathological features and prognosis of small gastrointestinal stromal tumors outside the stomach

Wang,Yong‑Peng; Li,Yi; Song,Chun

doi:10.3892/ol.2015.3631

Clinicopathological features and prognosis of small gastrointestinal stromal tumors outside the stomach

Authors:
- Yong‑Peng Wang
- Yi Li
- Chun Song
View Affiliations

Affiliations: Department of Colorectal Surgery, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042, P.R. China, Department of Pathology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning 110042, P.R. China
Published online on: August 25, 2015 https://doi.org/10.3892/ol.2015.3631
Pages: 2723-2730
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to assess the clinicopathological features and prognostic factors of primary small gastrointestinal stromal tumors (GISTs) outside the stomach. The clinical data, clinicopathological features and prognostic factors of 20 patients with a pathologically‑confirmed diagnosis of non‑gastric GIST that were treated at Liaoning Cancer Hospital & Institute between July 2006 and December 2013 were retrospectively analyzed. In total, 15 patients were male and 5 were female, with a median age of 58 years (range, 44‑82 years). A change in bowel habits was the original symptom of rectal small GISTs in 6 out of 8 patients, while patients with small GISTs in other locations demonstrated no overt symptoms and the lesions were detected by systematic examinations of other diseases or abdominal surgical procedures performed on other organs. In total, 19 patients out of the total 20 patients underwent surgery, and 1 patient with rectal GIST received continuous oral imatinib mesylate (400 mg once a day) instead of undergoing surgery. The mean diameter of tumors was 1.55±0.54 cm (range, 0.3‑2.0 cm) and the median was 1.70 cm. The pathomorphology of the lesions was mainly spindle cell, and immunohistochemistry revealed the expression rate of cluster of differentiation (CD)117, CD34 and discovered on GIST‑1 were 85, 80 and 70%. According to the mitosis index, small rectal GISTs were more frequent compared with other positions (P<0.05), while the frequency of small GISTs >1 cm in size was not significantly different from the frequency of small GISTs ≤1 cm in size (P=0.995). All 20 patients were followed up, with a median follow‑up duration of 49.5 months (range, 10.5‑94.4 months). At the end of the follow‑up period, tumor recurrence occurred in 5 patients and 1 patient succumbed following progression. According to the analysis of the tumor sites, the RFS time of patients with small rectal GISTs was significantly different than the RFS time in patients with small GISTs in other positions. The clinical symptoms of non‑gastric small GISTs were not evident and were challenging to detect. Small GISTs, regardless of size, possessed malignant potential and once detected, GISTs should be surgically resected. Lesions located in the rectum demonstrated an increased degree of malignancy and were more likely to recur. The tumor size and Ki67 index could not be considered as prognostic factors of non‑gastric small GISTs.

View Figures

View References

1	Huang H, Liu YX, Zhan ZL, Liang H, Wang P and Ren XB: Different sites and prognoses of gastrointestinal stromal tumors of the stomach: Report of 187 cases. World J Surg. 34:1523–1533. 2010. View Article : Google Scholar : PubMed/NCBI
2	Tran T, Davila JA and El-Serag HB: The epidemiology of malignant gastrointestinal stromal tumors: An analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 100:162–168. 2005. View Article : Google Scholar : PubMed/NCBI
3	Doğusoy G Bülbül: Turkish GIST Working Group: Gastrointestinal stromal tumors: A multicenter study of 1160 Turkish cases. Turk J Gastroenterol. 23:203–211. 2012.PubMed/NCBI
4	von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, Conrad EU III, DeLaney TF, Ganjoo KN, George S, et al: Gastrointestinal stromal tumors, version 2.2014. J Natl Compr Canc Netw. 12:853–862. 2014.PubMed/NCBI
5	Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, et al: Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer. 120:2325–2333. 2014. View Article : Google Scholar : PubMed/NCBI
6	Shen C, Chen H, Yin Y and Chen J, Zhang B, Chen Z and Chen J: Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor. Clinics (Sao Paulo). 69:758–762. 2014. View Article : Google Scholar : PubMed/NCBI
7	Bischof DA, Kim Y, Blazer DG III, Behman R, Karanicolas PJ, Law CH, Quereshy FA, Maithel SK, Gamblin TC, Bauer TW, et al: Surgical management of advanced gastrointestinal stromal tumors: An international multi-institutional analysis of 158 patients. J Am Coll Surg. 219:439–449. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ogata K, Mochiki E, Ojima H, Haga N, Fukuchi M, Aihara R, Ando H, Uchida N, Toyomasu Y, Suzuki M, et al: A multicenter long-term study of imatinib treatment for Japanese patients with unresectable or recurrent gastrointestinal stromal tumors. J Surg Oncol. 110:942–946. 2014. View Article : Google Scholar : PubMed/NCBI
9	Gao X, Xue A, Fang Y, Shu P, Ling J, Hu J, Hou Y, Shen K, Qin J, Sun Y, et al: Clinicopathological features of small gastrointestinal stromal tumors. Zhonghua Wei Chang Wai Ke Za Zhi. 18:338–341. 2015.(In Chinese). PubMed/NCBI
10	Sorour MA, Kassem MI, Ghazal A-H, El-Riwini MT and Abu Nasr A: Gastrointestinal stromal tumors (GIST) related emergencies. Int J Surg. 12:269–280. 2014. View Article : Google Scholar : PubMed/NCBI
11	Kawanowa K, Sakuma Y, Sakurai S, Hishima T, Iwasaki Y, Saito K, Hosoya Y, Nakajima T and Funata N: High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol. 37:1527–1535. 2006. View Article : Google Scholar : PubMed/NCBI
12	Casali PG, Jost L, Reichardt P, Schlemmer M and Blay JY: ESMO Guidelines Working Group: Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20(Suppl 4): 64–67. 2009.PubMed/NCBI
13	Joensuu H: Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 39:1411–1419. 2008. View Article : Google Scholar : PubMed/NCBI
14	Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, et al: NCCN Task Force report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 8(Suppl 2): S1–S41. (quiz S42-S44). 2010.PubMed/NCBI
15	Rossi S, Gasparotto D, Toffolatti L, Pastrello C, Gallina G, Marzotto A, Sartor C, Barbareschi M, Cantaloni C, Messerini L, et al: Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 34:1480–1491. 2010. View Article : Google Scholar : PubMed/NCBI
16	Fang YJ, Cheng TY, Sun MS, Yang CS, Chen JH, Liao WC and Wang HP: Suggested cutoff tumor size for management of small EUS-suspected gastric gastrointestinal stromal tumors. J Formos Med Assoc. 111:88–93. 2012. View Article : Google Scholar : PubMed/NCBI
17	Agaimy A, Wünsch PH, Sobin LH, Lasota J and Miettinen M: Occurrence of other malignancies in patients with gastrointestinal stromal tumors. Semin Diagn Pathol. 23:120–129. 2006. View Article : Google Scholar : PubMed/NCBI
18	Wang YP, Li Y and Song C: Metachronous multiple gastrointestinal stromal tumors and adenocarcinoma of the colon: A case report. Oncol Lett. 8:1123–1126. 2014.PubMed/NCBI
19	Agaimy A, Wünsch PH, Dirnhofer S, Bihl MP, Terracciano LM and Tornillo L: Microscopic gastrointestinal stromal tumors in esophageal and intestinal surgical resection specimens: A clinicopathologic, immunohistochemical, and molecular study of 19 lesions. Am J Surg Pathol. 32:867–873. 2008. View Article : Google Scholar : PubMed/NCBI
20	Chetty R: Small and microscopically detected gastrointestinal stromal tumours: An overview. Pathology. 40:9–12. 2008. View Article : Google Scholar : PubMed/NCBI
21	Abraham SC, Krasinskas AM, Hofstetter WL, Swisher SG and Wu TT: ‘Seedling’ mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. Am J Surg Pathol. 31:1629–1635. 2007. View Article : Google Scholar : PubMed/NCBI
22	He YL: Consensus and controversy of surgical diagnosis and treatment for gastrointestinal stromal tumor. Zhonghua Wei Chang Wai Ke Za Zhi. 16:201–203. 2013.(In Chinese). PubMed/NCBI
23	Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG, Singer S, Besmer P, Brennan MF and Antonescu CR: Tumor mitotic rate, size and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer. 112:608–615. 2008. View Article : Google Scholar : PubMed/NCBI
24	Yang J, Feng F, Li M, Sun L, Hong L, Cai L, Wang W, Xu G and Zhang H: Surgical resection should be taken into consideration for the treatment of small gastric gastrointestinal stromal tumors. World J Surg Oncol. 11:2732013. View Article : Google Scholar : PubMed/NCBI
25	Kim MY, Park YS, Choi KD, Lee JH, Choi KS, Kim H, Song HJ, Lee GH, Jung HY, Kim JH, et al: Predictors of recurrence after resection of small gastric gastrointestinal stromal tumors of 5 cm or less. J Clin Gastroenterol. 46:130–137. 2012. View Article : Google Scholar : PubMed/NCBI
26	Corless CL, McGreevey L, Haley A, Town A and Heinrich MC: KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol. 160:1567–1572. 2002. View Article : Google Scholar : PubMed/NCBI
27	De Vogelaere K, Van Loo I, Peters O, Hoorens A, Haentjens P and Delvaux G: Laparoscopic resection of gastric gastrointestinal stromal tumors (GIST) is safe and effective, irrespective of tumor size. Surg Endosc. 26:2339–2345. 2012. View Article : Google Scholar : PubMed/NCBI
28	Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH and Lasota J: Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 25:1121–1133. 2001. View Article : Google Scholar : PubMed/NCBI
29	Sun LF, He JJ, Yu SJ, Xu JH, Wang JW, Li J, Song YM, Ding KF and Zheng S: Transsacral excision with pre-operative imatinib mesylate treatment and approach for gastrointestinal stromal tumors in the rectum: A report of two cases. Oncol Lett. 8:1455–1460. 2014.PubMed/NCBI
30	Wilkinson MJ, Fitzgerald JE, Strauss DC, Hayes AJ, Thomas JM, Messiou C, Fisher C, Benson C, Tekkis PP and Judson I: Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib. Br J Surg. 102:965–971. 2015. View Article : Google Scholar : PubMed/NCBI
31	Liu H, Yan Z, Liao G and Yin H: Treatment strategy of rectal gastrointestinal stromal tumor (GIST). J Surg Oncol. 109:708–713. 2014. View Article : Google Scholar : PubMed/NCBI
32	Wang JP, Wang T, Huang MJ, Wang L, Kang L and Wu XJ: The role of neoadjuvant imatinib mesylate therapy in sphincter-preserving procedures for anorectal gastrointestinal stromal tumor. Am J Clin Oncol. 34:314–316. 2011. View Article : Google Scholar : PubMed/NCBI
33	Dong C, Jun-Hui C, Xiao-Jun Y, Mei K, Bo W, Chen-Fe J and Wei-Li Y: Gastrointestinal stromal tumors of the rectum: Clinical, pathologic, immunohistochemical characteristics and prognostic analysis. Scand J Gastroenterol. 42:1221–1229. 2007. View Article : Google Scholar : PubMed/NCBI
34	Chen BX, Hao DM and Zhang ZX: Prognostic analysis of 40 cases with rectal gastrointestinal stromal tumor. Zhonghua Wei Chang Wai Ke Za Zhi. 15:263–265. 2012.(In Chinese). PubMed/NCBI
35	Pathmanathan N and Balleine RL: Ki67 and proliferation in breast cancer. J Clin Pathol. 66:512–516. 2013. View Article : Google Scholar : PubMed/NCBI
36	Koumarianou A, Chatzellis E, Boutzios G, Tsavaris N and Kaltsas G: Current concepts in the diagnosis and management of poorly differentiated gastrointestinal neuroendocrine carcinomas. Endokrynol Pol. 64:60–72. 2013.PubMed/NCBI
37	Zhao WY, Xu J, Wang M, Zhang ZZ, Tu L, Wang CJ, Lin TL, Shen YY, Liu Q and Cao H: Prognostic value of Ki67 index in gastrointestinal stromal tumors. Int J Clin Exp Pathol. 7:2298–2304. 2014.PubMed/NCBI
38	Wang H, Chen P, Liu XX, Zhao W, Shi L, Gu XW, Zhu CR, Zhu HH and Zong L: Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors. World J Surg Oncol. 12:892014. View Article : Google Scholar : PubMed/NCBI